Apricus files protocol of PrevOnco Phase 3 clinical trial for FDA SPA program Apricus Biosciences.

By Onyx Pharmaceuticals, Inc. And Bayer Health care Pharmaceuticals, Inc., with close to $1 billion in sales, and is accepted in more than 90 countries for the treating sufferers with hepatocellular carcinoma. Dr. Bassam Damaj, Chief and President Executive Officer of Apricus Bio, noted, ‘Fifteen years worth of encounter using lansoprazol to treat ulcers has shown that the drug can be safe for human being use. We’ve also seen strong anti-cancers activity in mice bearing human liver tumors. Because of this, we are optimistic that PrevOnco to do well in the clinic. The Company may seek FDA approval to switch the existing lansoprazole formulation with the NexACT formulation of lansoprazole following a Phase I individual pharmacokinetic equivalency bridging study..Church-centered education program improves diet, exercise habits among Latino adults with diabetes Latino adults with diabetes who participated in a church-based education program reported consuming less high-fat food and exercising more following a trial intervention program run by experts from University of Chicago's Division of Medication. The Picture Good Wellness program, located in the populous city;s South Lawndale/Little Village neighborhood, included an eight-week series of classes led by trained community users. The participants, mostly older Latino women, all had a prior analysis of diabetes and had been recruited from two Catholic church communities. The total results of the study, published April 28 in the Journal of General Internal Medicine, demonstrate the effectiveness of partnering with faith-structured organizations to provide diabetes education in the Latino community.

Other Posts From Category "clinical":

Related Posts